Kaushik Ghoshal sold $2.3M of RMD
Chief Commercial Officer, SaaS at RESMED INC. 9,745 shares at an average of $239.31, traded Mar 10, 2025, filed Mar 11, 2025.
Score components
- +15RoleOfficer
- +25Trade size$2.3M at market
- +20Share of holdings soldSold 50% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.8%, 3m +12.1%, 6m +24.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001127602-25-009051, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 10, 2025 | MOption exercise ResMed Common Stock10b5-1 | +169 | $146.34 | $25k | 9,894 | Mar 11, 2025 |
| Mar 10, 2025 | MOption exercise ResMed Common Stock10b5-1 | +105 | $211.76 | $22k | 9,999 | Mar 11, 2025 |
| Mar 10, 2025 | MOption exercise ResMed Common Stock10b5-1 | +3,589 | $146.34 | $525k | 13,588 | Mar 11, 2025 |
| Mar 10, 2025 | MOption exercise ResMed Common Stock10b5-1 | +5,882 | $211.76 | $1.2M | 19,470 | Mar 11, 2025 |
| Mar 10, 2025 | SOpen-market sale ResMed Common Stock10b5-1 | -9,745 | $239.31 | $2.3M | 9,725 | Mar 11, 2025 |
| Mar 10, 2025 | MOption exercise ResMed Common Stock Optionsderivative10b5-1 | -169 | $0.00 | $0 | 0 | Mar 11, 2025 |
| Mar 10, 2025 | MOption exercise ResMed Common Stock Optionsderivative10b5-1 | -105 | $0.00 | $0 | 0 | Mar 11, 2025 |
| Mar 10, 2025 | MOption exercise ResMed Common Stock Optionsderivative10b5-1 | -5,882 | $0.00 | $0 | 0 | Mar 11, 2025 |
| Mar 10, 2025 | MOption exercise ResMed Common Stock Optionsderivative10b5-1 | -3,589 | $0.00 | $0 | 0 | Mar 11, 2025 |
Related signals
Other insiders at RESMED INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | RESMED INC | Michael J. Farrell Chairman and CEO | $1.1M 4,991 shares | -1% | |
| 23Weak | RESMED INC | Michael J. Farrell Chairman and CEO | $1.1M 4,991 shares | -1% | |
| 16Weak | RESMED INC | Peter C Farrell director | $228k 970 shares | -2% | |
| 23Weak | RESMED INC | Michael J. Farrell Chairman and CEO | $1.0M 4,991 shares | -1% | |
| 33Weak | RESMED INC | Peter C Farrell director | $1.8M 8,000 shares | -13% | |
| 15Weak | RESMED INC | Michael J. Farrell Chairman and CEO | $1.1M 4,991 shares | -1% | |
| 15Weak | RESMED INC | Michael J. Farrell Chairman and CEO | $968k 4,991 shares | -1% | |
| 15Weak | RESMED INC | Michael J. Farrell Chairman and CEO | $1.0M 4,991 shares | -1% | |
| 30Weak | RESMED INC | Michael J. Farrell Chairman and CEO | $1.1M 4,991 shares | -1% | |
| 29Weak | RESMED INC | Brett Sandercock Chief Financial Officer | $224k 1,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.